|0.4247||-0.0002||-0.05%||Vol 227.85K||1Y Perf -59.92%|
|Aug 11th, 2022 15:59 DELAYED|
|- -||- -%|
|Target Price||4.08||Analyst Rating||Strong Buy 1.00|
|Potential %||860.68||Finscreener Ranking||★★★★★ 61.19|
|Insiders Trans % 3/6/12 mo.||-/-/100||Value Ranking||★★★★ 57.35|
|Insiders Value % 3/6/12 mo.||-/-/100||Growth Ranking||★★★★ 59.11|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/100||Income Ranking||— -|
|Price Range Ratio 52W %||8.49||Earnings Rating||Buy|
|Market Cap||41.40M||Earnings Date||15th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||15th Aug 2022|
|Estimated EPS Next Report||-0.04|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||197.82K|
|Avg. Monthly Volume||148.89K|
|Avg. Quarterly Volume||179.61K|
Cocrystal Pharma Inc. (NASDAQ: COCP) stock closed at 0.4247 per share at the end of the most recent trading day (a -0.05% change compared to the prior day closing price) with a volume of 227.85K shares and market capitalization of 41.40M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Cocrystal Pharma Inc. CEO is Gary L. Wilcox.
The one-year performance of Cocrystal Pharma Inc. stock is -59.92%, while year-to-date (YTD) performance is -34.66%. COCP stock has a five-year performance of -92.54%. Its 52-week range is between 0.35 and 1.23, which gives COCP stock a 52-week price range ratio of 8.49%
Cocrystal Pharma Inc. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 0.57, a price-to-sale (PS) ratio of 132.06, a price to cashflow ratio of 54.20, a PEG ratio of 2.32, a ROA of -24.81%, a ROC of -24.71% and a ROE of -25.51%. The company’s profit margin is -5.26%, its EBITDA margin is -2 276.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cocrystal Pharma Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.04 for the next earnings report. Cocrystal Pharma Inc.’s next earnings report date is 15th Aug 2022.
The consensus rating of Wall Street analysts for Cocrystal Pharma Inc. is Strong Buy (1), with a target price of $4.08, which is +860.68% compared to the current price. The earnings rating for Cocrystal Pharma Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cocrystal Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cocrystal Pharma Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 25.56, ATR14 : 0.03, CCI20 : 38.25, Chaikin Money Flow : -0.04, MACD : 0.00, Money Flow Index : 55.00, ROC : 1.17, RSI : 40.63, STOCH (14,3) : 88.12, STOCH RSI : 1.00, UO : 56.48, Williams %R : -11.88), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cocrystal Pharma Inc. in the last 12-months were: Richard C. Pfenniger (Buy at a value of $41 120)
Thu, 24 Mar 2022 10:25 GMT Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and iTeos Therapeutics (ITOS)- TipRanks. All rights reserved.
Tue, 08 Feb 2022 13:25 GMT Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Lantern Pharma (LTRN)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.